Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06717347 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
A Phase 3 study of Diffuse Large B Cell Lymphoma, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,046
- Enrollment target
- 20
- Study locations
NCT06717347 is a Phase 3 study of Diffuse Large B Cell Lymphoma that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 1,046 participants, above the 209-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (400% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT06717347, a Phase 3 study of Diffuse Large B Cell Lymphoma, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,046 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- BIOLOGICAL Rituximab
- BIOLOGICAL Zilovertamab vedotin
- BIOLOGICAL Rituximab Biosimilar
Study Locations (20)
California
- Providence Medical Foundation-Oncology ( Site 0168) - Fullerton
- Cancer Blood and Specialty Clinic ( Site 0109) - Los Alamitos
- Cedars-Sinai Medical Center ( Site 0115) - Los Angeles
- Pacific Hematology Oncology Associates ( Site 0131) - San Francisco
Florida
- Clermont Oncology Center ( Site 0182) - Clermont
- Bioresearch Partner ( Site 0157) - Hialeah
- Orlando Health Cancer Institute ( Site 0169) - Ocoee
- Mid Florida Hematology and Oncology Center ( Site 0172) - Orange City
Arizona
- Banner MD Anderson Cancer Center ( Site 0165) - Gilbert
- Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0167) - Phoenix
- The University of Arizona Cancer Center - North Campus ( Site 0124) - Tucson
Kentucky
- University of Kentucky ( Site 0106) - Lexington
- Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0163) - Louisville
Missouri
- Circuit Clinical - SSM Health Cancer Care DePaul ( Site 0166) - Bridgeton
- Truman Medical Center ( Site 0122) - Kansas City
Colorado
- Lutheran Hospital - Cancer Centers of Colorado ( Site 0180) - Golden
Illinois
- Cancer Care Specialists of Illinois ( Site 0152) - O'Fallon
Indiana
- Fort Wayne Medical Oncology and Hematology ( Site 0149) - Fort Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,046 participants |
| Start Date | 2025-01-27 |
| Est. Completion | 2032-03-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06717347
The ClinicalTrials.gov registry entry for NCT06717347 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,046 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 209-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (400% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT06717347 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06717347 about?
NCT06717347 is a clinical study titled "A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)". The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
What is the current status of trial NCT06717347?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,046 participants. The study started on 2025-01-27. Estimated completion is 2032-03-29.
What conditions does trial NCT06717347 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma.
What interventions are being tested in trial NCT06717347?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Rituximab (BIOLOGICAL), Zilovertamab vedotin (BIOLOGICAL), Rituximab Biosimilar (BIOLOGICAL).
Who is sponsoring clinical trial NCT06717347?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06717347 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term Extension Study of PCI-32765 (Ibrutinib)
RECRUITING · Phase 3
-
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
RECRUITING · Phase 3
-
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
ACTIVE NOT RECRUITING · Phase 3
-
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 3
-
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.